Avidity Biosciences Expands Role of Michael MacLean to Chief Financial and Chief Business Officer | 2022-04-05 | Press Releases

SAN DIEGO, April 5, 2022 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical corporation fully commited to providing a new course of RNA therapeutics termed Antibody Oligonucleotide Conjugates (AOCs™), currently declared that Michael MacLean, currently the main monetary officer, has expanded his role to involve responsibilities as chief company officer.

(PRNewsfoto/Avidity Biosciences, Inc.)

“Mike’s management, strategic pondering and working experience have been instrumental in the accomplishment of Avidity in excess of these past two years as we transitioned into a publicly-traded, medical-phase biopharmaceutical firm,” stated Sarah Boyce, president and chief executive officer. “I am pleased that he is having on these expanded tasks as his enter and steering will be invaluable to the crew as we progress our clinical growth packages and development our revolutionary AOC platform technological know-how throughout a array of therapeutic regions.”

As the chief money and chief organization officer, Mr. MacLean now potential customers finance, business growth, supply chain and investor relations as Avidity innovations its AOC system and functions toward the target of having 3 unique rare condition packages in the clinic by the stop of 2022.

Mr. MacLean delivers many years of sector practical experience to Avidity, with deep encounter in funding biotechnology providers, building strategic strategies, partnering novel systems and advancing novel therapies in the scarce and orphan sickness places by way of to commercialization. Prior to joining Avidity, Mr. MacLean served as chief money officer of Akcea Therapeutics, Inc. where he led the buildout of Akcea’s fiscal and world-wide infrastructure. Prior to Akcea, Mr. MacLean served as main financial officer of PureTech Well being, plc, as nicely as chief accounting officer of Biogen Inc. the place he led the company’s around the globe finance functions.

“I am happy to be aspect of the Avidity workforce that is effectively on the route to acknowledging its eyesight to profoundly enhance the lives of men and women influenced by serious health conditions. We have assembled a gifted group and I appear ahead to continuing to operate intently with them and other senior leaders as we produce on our eyesight,” explained Mr. MacLean, chief fiscal and main business enterprise officer.

About Avidity

Avidity Biosciences, Inc.’s mission is to profoundly enhance people’s life by offering a new class of RNA therapeutics – Antibody Oligonucleotide Conjugates (AOCsTM). Avidity’s proprietary AOCs are intended to mix the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to goal the root bring about of diseases beforehand untreatable with RNA therapeutics. Avidity is on keep track of to have three plans in clinical improvement by the stop of 2022. The firm’s guide merchandise applicant, AOC 1001, is developed to deal with individuals with myotonic dystrophy type 1 (DM1). AOC 1001 has commenced medical screening with the ongoing Section 1/2 MARINATM trial in grownups with DM1. The next packages in the firm’s advancing and increasing pipeline are AOC 1044, the direct of a few courses for the treatment of DMD, and AOC 1020, built to address individuals residing with FSHD. Avidity anticipates equally programs will enter the clinic by the conclusion of 2022. Avidity is also broadening the attain of AOCs past muscle mass tissues through both interior discovery initiatives and crucial partnerships as the business proceeds to deliver on the RNA revolution. Avidity is headquartered in San Diego. For extra facts about our science, pipeline and people today, make sure you pay a visit to www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.

Ahead-Hunting Statements

Avidity cautions readers that statements contained in this press launch relating to matters that are not historic facts are ahead-on the lookout statements and cautions readers not to position undue reliance on these forward-seeking statements. These statements are dependent on the firm’s present beliefs and expectations, and the firm undertakes no obligation to update these kinds of statements to replicate activities that come about or circumstances that exist right after the day hereof. These kinds of forward-wanting statements include, but are not limited to, statements relating to: the opportunity to create a meaningful pipeline of novel AOC therapeutics the progression of medical systems for AOCs and the broad prospective of AOCs to address uncommon and severe health conditions. The inclusion of ahead-looking statements should not be regarded as a illustration by Avidity that any of these options will be reached. True success might differ from individuals set forth in this push release thanks to the challenges and uncertainties inherent in the business enterprise, including, without having limitation: Avidity is early in its improvement endeavours Avidity’s method to the discovery and development of merchandise candidates based mostly on its AOC system is unproven, and the organization does not know no matter whether it will be in a position to acquire any products of professional price probable delays in the graduation, enrollment and completion of clinical trials the achievements of its preclinical research and medical trials for the firm’s solution candidates the results of preclinical research and early scientific trials are not essentially predictive of upcoming results unforeseen adverse aspect effects or inadequate efficacy of its item candidates that could limit their improvement, regulatory approval and/or commercialization, or may possibly final result in remembers or product or service liability claims and other threats explained in prior press releases and in filings with the Securities and Trade Commission (SEC). All forward-searching statements are capable in their entirety by this cautionary assertion, which is produced underneath the secure harbor provisions of the Private Securities Litigation Reform Act of 1995.

Enterprise Get hold of:

Kath Gallagher

[email protected]

(858) 401-7900

Cision Look at first material to download multimedia:https://www.prnewswire.com/information-releases/avidity-biosciences-expands-position-of-michael-maclean-to-chief-financial-and-chief-small business-officer-301517438.html

Source Avidity Biosciences, Inc.